Development of new therapeutic artificial virus with the ability of escape from endocytosis

2012 Fiscal Year Final Research Report

• Project/Area Number: 23791543
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Kyushu University
• Principal Investigator: EGAMI Takuya 九州大学, 医学研究院, 共同研究員 (40507787)
• Project Period (FY): 2011 – 2012
• Keywords: エンドサイトーシス / アデノウイルス / 薬剤内包型人工ウイルス

Research Abstract

We find out the endocytosis pathway at pancreatic cancer and create an artificial virus contained anti-cancer drug. Pancreatic cancer cells highly expressed integrin β3 more than β5 are decreased expression of adenovirus-transfected gene, and pancreatic cancer cells silencing expression of integrin β 3 showed high expression of adenovirus-transfected gene. We altered an artificial virus silencing integrin β3 by protease signaling

Research Products

• [Journal Article] Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells (2011)
  • Author(s): Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto M, Matsumoto K, Tanaka M
  • Journal Title: Anticancer Research Volume: 31(4) Pages: 1279-1288
• [Journal Article] Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway (2011)
  • Author(s): Yasui T, Ohuchida K, Zhao M, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K, Tanaka M
  • Journal Title: Cancer science Volume: 102(2) Pages: 484-491